

SEQUENCE LISTING

<110> Shashoua, Victor

<120> Compositions and Methods for Counteracting Effects
of Reactive Oxygen Species and Free Radicals

<130> CMX-001.1 US

<150> 60/166,381

<151> 1999-11-18

<160> 36

<170> PatentIn version 3.0

<210> 1

<211> 12

<212> PRT

<213> synthetic

<220>

<221> PEPTIDE

<222> (1)..(12)

<400> 1

Gln Tyr Lys Leu Gly Ser Lys Thr Gly Pro Gly Gln
1 5 10

<210> 2

<211> 6

<212> PRT

<213> synthetic

<220>

<221> PEPTIDE

<222> (1)..(6)

<400> 2

Gln Thr Leu Gln Phe Arg
1 5

<210> 3

<211> 7

<212> PRT

<213> synthetic

<220>

<221> PEPTIDE

<222> (1)..(7)

<223> amino acid positions designated Xaa may be
varied to form alternative peptide compounds
of the invention, as explained in the disclosure

<400> 3

Xaa Gly Xaa Xaa Xaa Xaa Xaa
1 5

<210> 4
<211> 5
<212> PRT
<213> synthetic

<220>
<221> PEPTIDE
<222> (1)..(5)

<400> 4

Asp Gly Asp Gly Asp
1 5

<210> 5
<211> 6
<212> PRT
<213> synthetic

<220>
<221> PEPTIDE
<222> (1)..(6)

<400> 5

Asp Gly Asp Gly Phe Ala
1 5

<210> 6
<211> 7
<212> PRT
<213> synthetic

<220>
<221> PEPTIDE
<222> (1)..(7)

<400> 6

Asp Gly Asp Gly Asp Phe Ala
1 5

<210> 7
<211> 7
<212> PRT
<213> synthetic

<220>
<221> PEPTIDE
<222> (1)..(7)

<400> 7

Asp Gly Asn Gly Asp Phe Ala
1 5

<210> 8
<211> 7
<212> PRT
<213> synthetic

<220>
<221> PEPTIDE
<222> (1) .. (7)

<400> 8

Asn Gly Asn Gly Asp Phe Ala
1 5

<210> 9
<211> 7
<212> PRT
<213> synthetic

<220>
<221> PEPTIDE
<222> (1) .. (7)

<400> 9

Asn Gly Asp Gly Asp Phe Ala
1 5

<210> 10
<211> 8
<212> PRT
<213> synthetic

<220>
<221> PEPTIDE
<222> (1) .. (8)
<223> amino acid positions designated Xaa may be
varied to form alternative peptide compounds
of the invention, as explained in the disclosure

<400> 10

Xaa Xaa Met Thr Leu Thr Gln Pro
1 5

<210> 11
<211> 6
<212> PRT
<213> synthetic

<220>
<221> PEPTIDE

<222> (1)..(6)

<400> 11

Met Thr Leu Thr Gln Pro
1 5

<210> 12

<211> 8

<212> PRT

<213> synthetic

<220>

<221> PEPTIDE

<222> (1)..(8)

<400> 12

Ser Lys Met Thr Leu Thr Gln Pro
1 5

<210> 13

<211> 6

<212> PRT

<213> synthetic

<220>

<221> PEPTIDE

<222> (1)..(6)

<400> 13

Glu Thr Leu Gln Phe Arg
1 5

<210> 14

<211> 8

<212> PRT

<213> synthetic

<220>

<221> PEPTIDE

<222> (1)..(8)

<400> 14

Gln Tyr Ser Ile Gly Gly Pro Gln
1 5

<210> 15

<211> 8

<212> PRT

<213> synthetic

<220>

<221> PEPTIDE

<222> (1)..(8)

<400> 15

Ser Asp Arg Ser Ala Arg Ser Tyr
1 5

<210> 16
<211> 12
<212> PRT
<213> synthetic

<220>
<221> PEPTIDE
<222> (1)..(12)

<400> 16

Asp Gly Asp Gly Asp Phe Ala Ile Asp Ala Pro Glu
1 5 10

<210> 17
<211> 5
<212> PRT
<213> synthetic

<220>
<221> PEPTIDE
<222> (1)..(5)

<400> 17

Asn Gly Asn Gly Asp
1 5

<210> 18
<211> 5
<212> PRT
<213> synthetic

<220>
<221> PEPTIDE
<222> (1)..(5)

<400> 18

Asp Gly Asn Gly Asp
1 5

<210> 19
<211> 5
<212> PRT
<213> synthetic

<220>
<221> PEPTIDE
<222> (1)..(5)

<400> 23

[illegible]

Asn Gly Asp Gly Phe Ala
1 5

<210> 24
<211> 8
<212> PRT
<213> synthetic

<220>
<221> PEPTIDE
<222> (1)..(8)

<400> 24

Lys Lys Glu Thr Leu Gln Phe Arg
1 5

<210> 25
<211> 8
<212> PRT
<213> synthetic

<220>
<221> PEPTIDE
<222> (1)..(8)

<400> 25

Lys Lys Gln Thr Leu Gln Phe Arg
1 5

<210> 26
<211> 14
<212> PRT
<213> synthetic

<220>
<221> PEPTIDE
<222> (1)..(14)

<400> 26

Lys Lys Asp Gly Asp Gly Asp Phe Ala Ile Asp Ala Pro Glu
1 5 10

<210> 27
<211> 14
<212> PRT
<213> synthetic

<220>
<221> PEPTIDE
<222> (1)..(14)

<400> 27

Lys Lys Gln Tyr Lys Leu Gly Ser Lys Thr Gly Pro Gly Gln
 1 5 10

<210> 28
 <211> 9
 <212> PRT
 <213> synthetic

<220>
 <221> PEPTIDE
 <222> (1)..(9)

<400> 28

Lys Lys Asp Gly Asp Gly Asp Phe Ala
 1 5

<210> 29
 <211> 25
 <212> DNA
 <213> synthetic

<220>
 <221> primer sequence
 <222> (1)..(25)

<400> 29
 atcccaatca ctccacaggc caagc

25

<210> 30
 <211> 25
 <212> DNA
 <213> synthetic

<220>
 <221> primer sequence
 <222> (1)..(25)

<400> 30
 gagacctggg caatgtgact gctgg

25

<210> 31
 <211> 25
 <212> DNA
 <213> synthetic

<220>
 <221> primer sequence
 <222> (1)..(25)

<400> 31
 gcccgagtcc aggctcttct ggacc

25

<210> 32

<211> 25
<212> DNA
<213> synthetic

<220>
<221> primer sequence
<222> (1)..(25)

<400> 32
ttggcagcta tgtgagagcc ggcct

25

<210> 33
<211> 21
<212> DNA
<213> synthetic

<220>
<221> protein_bind
<222> (1)..(21)

<400> 33
cgcttgatga ctcagccgga a

21

<210> 34
<211> 21
<212> DNA
<213> synthetic

<220>
<221> mutant protein_bind
<222> (1)..(21)
<223> mutated sequence of protein binding site
for transcription factor AP-1

<400> 34
cgcttgatga cttggccgga a

21

<210> 35
<211> 21
<212> DNA
<213> synthetic

<220>
<221> protein_bind
<222> (1)..(21)

<400> 35
cgcttgatga gtcagccgga a

21

<210> 36
<211> 21

<213> synthetic

$\langle 220 \rangle$

```
<221> mutant protein_bind
```

 $\langle 222 \rangle \quad (1) \dots (21)$

<223> mutated sequence of protein binding site
for transcription factor AP-1

<400> 36

cgcttgatga gttggccgga a

21

1

1

1. *What is the purpose of the study?*
 2. *What are the research questions or hypotheses?*
 3. *What is the study design?*
 4. *What is the sample size and how was it selected?*
 5. *What are the variables being studied?*
 6. *What are the data collection methods?*
 7. *What are the results of the study?*
 8. *What are the conclusions and implications of the study?*